2011
&agr;4&bgr;2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties
Mineur YS, Einstein EB, Seymour PA, Coe JW, O'Neill BT, Rollema H, Picciotto MR. &agr;4&bgr;2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties. Behavioural Pharmacology 2011, 22: 291-299. PMID: 21566524, PMCID: PMC3227135, DOI: 10.1097/fbp.0b013e328347546d.Peer-Reviewed Original ResearchConceptsNovelty-suppressed feeding testPartial agonistNicotinic acetylcholine receptor partial agonistAcceptable side effect profileAntidepressant-like effectsAntidepressant-like propertiesSide effect profileTail suspension testForced-swim testReceptor partial agonistLow intrinsic efficacyNicotinic acetylcholine receptorsAntidepressant efficacyFeeding testsReduced immobilityAntidepressant propertiesMood disordersNicotinic compoundsΑ4β2 nAChRsAcetylcholine receptorsLocomotor activityIntrinsic efficacyFunctional efficacySubtype selectivityTime points
2008
Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease.
Picciotto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Frontiers In Bioscience-Landmark 2008, 13: 492-504. PMID: 17981563, DOI: 10.2741/2695.Peer-Reviewed Original ResearchConceptsAbility of nicotineNeurodegenerative disordersRole of nAChRsHuman neurodegenerationNeuroprotective agentsParkinson's diseaseDevelopmental stagesCellular effectsNicotine-mediated neuroprotectionRegimen of administrationDrug discoveryNicotine neuroprotectionNeuronal survivalNeuronal deathEpidemiological studiesNicotinic compoundsAlzheimer's diseaseRecent studiesNeuroprotectionDiseaseNicotineCompelling evidenceNAChRsVivoFull understanding